IP Library › Granted Patent US 12,606,608
Granted Patent B2
US 12,606,608 · App. 17/614,900 · Granted Apr 21, 2026

Modified NK-92 cells, and therapeutic and diagnostic uses thereof

Inventors: Udo Hartwig (Nackenheim, DE); Jan Wernersbach (Mainz, DE); Catherine Woelfel (Mainz, DE)
Assignee: Universitatsmedizin Der Johannes Gutenberg-Univeristat Mainz
C07K14/70514A61K40/11A61K40/15A61K40/32A61K40/4224A61P35/02C07K14/7051C07K14/70517C12N5/0646
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,608
App. No.
17/614,900
Granted
Apr 21, 2026
Kind
B2
Abstract

Modified natural killer 92 (NK-92) cells and their use in cancer therapy, in particular for the prevention or treatment of solid tumours such as sarcomas, carcinomas, melanoma and lymphoma, and non-solid tumours such as leukaemia and related disorders. Embodiments of the invention further relate to the use of the modified NK-92 cells for in vitro diagnosis, diagnostics and/or screening, methods for the preparation of a modified NK-92 that is specific for a target antigen of a target cell in a subject, and to an expression vector, comprising the nucleic acid sequences of an antigen-specific functional T cell receptor (TCR), CD3, CD4 and/or CD8.

Claims (16)

1 . A modified natural killer 92 (NK-92) cell co-expressing:

(1) an antigen-specific functional T cell receptor (TCR) comprising an alpha chain and a beta chain,

(2) CD3, said CD3 consisting of a CD3 γ chain, a δ chain, two ε chains, and two ζ chains, and

(3) CD8 and/or CD4.

2 . The modified NK-92 cell according to claim 1 , wherein the TCR originates from 5B2, 25F2 or 5H11 cells.

3 . The modified NK-92 cell according to claim 2 , wherein the 5B2 TCR is composed of an alpha chain encoded by SEQ ID NO: 1 and a beta chain encoded by SEQ ID NO: 2.

4 . The modified NK-92 cell according to claim 2 , wherein the 25F2 TCR is composed of an alpha chain encoded by SEQ ID NO: 3 and a beta chain encoded by SEQ ID NO: 4.

5 . The modified NK-92 cell according to claim 2 , wherein the 5H11 TCR is composed of an alpha chain encoded by SEQ ID NO: 5 and a beta chain encoded by SEQ ID NO: 6.

6 . The modified NK-92 cell according to claim 1 , wherein the TCR is a fusion protein with CD3 and CD8 or CD4 expressed by the NK-92 cell.

7 . A modified natural killer 92 (NK-92) cell according to claim 1 for use as a medicament.

8 . A modified natural killer 92 (NK-92) cell according to claim 1 for use in cancer therapy.

9 . The modified NK-92 cell according to claim 8 , wherein the cancer is a solid tumour.

10 . A modified natural killer 92 (NK-92) cell according to claim 1 for use in the prevention or treatment of leukaemia and related disorders.

11 . The modified NK-92 cell according to claim 10 , wherein the leukaemia is selected from acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML), chronic myelomonocytic leukaemia (CMML), eosinophilic leukaemia, hairy cell leukaemia, Hodgkin's lymphoma (HL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), myeloproliferative disorders or myelodysplastic syndrome (MDS).

12 . A pharmaceutical composition, comprising a modified natural killer 92 (NK-92) cell according to claim 1 , and at least one pharmaceutically acceptable carrier or excipient.

13 . The modified NK-92 cell according to claim 9 , wherein the solid tumour is a sarcoma, a carcinoma, a melanoma, or a lymphoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2022
From: HARTWIG, UDO; WERNERSBACH, JAN; WOELFEL, CATHERINE
To: UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
Reel/Frame 059312/0725 →
Priority Claims (1)
EP 19180008 · Jun 13, 2019 · regional
Continuity (1)
Related Publication 20220233596A1 · Jul 28, 2022
References Cited (29)
US 20160083449A1 · Schmitt et al. · 2016 [cited by applicant]
WO WO2016116601 · 2016 [cited by applicant]
WO WO2016116601A1 · 2016 [cited by examiner]
WO WO2018129199 · 2018 [cited by applicant]
Mahdavi et al., “production and characterization of new anti-her2 monoclonal antibodies” Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (Year: 2015). [cited by examiner]
Mensali et al. “NK cells specifically TCR dressed to kill cancer cells” Ebiomedicine (Year: 2019). [cited by examiner]
Weng “Numbers and odds: TCR reportoire size and its age changes impacting on T cell functions” Semin Immunol (Year: 2023). [cited by examiner]
Schaefer and Rost, “predict impact of single amino acid change upon protein structure” BMC Genomics (Year: 2012). [cited by examiner]
Schaefer & Rost, “Impact impact of single amino acid change upon protein structure” BMC GEnomics (Year: 2012). [cited by examiner]
Spinsanti, P. et al., “Wilms' tumor gene expression by normal and malignant human B lymphocytes”, Leukemia & Lymphoma, vol. 38(5-6), pp. 611-619, Database Medline[Online], XP002795789, database aaccession No. NLM1095398… [cited by applicant]
Wernersbach, J. et al., “PF439 exploring the therapeutic potential of t-cell-receptor redirected CD3+ natural killer cells for adoptive cellular therapy to acute myeloid leukemia”, Hemasphere, vol. 3(S1), pp. 172-173, d… [cited by applicant]
Cheng, M. et al., “Natural killer cell lines in tumor immunoltherapy”, Frontiers in Medicine., vol. 6(1), pp. 56-66, doi: 10.1007/s11684-012-0177-7, (Mar. 2012) Abs. [cited by applicant]
Sharpe, M. et al., “Genetically modified T cells in cancer therapy: opportunities and challenges”, Dis. Model Mech., vol. 8(4), pp. 337-350, (Apr. 2015). [cited by applicant]
Mensali, N. et al., “NK cells specifically TCR-dressed to kill cancer cells”, EBioMedicine, vol. 40, pp. 106-117, (2019). [cited by applicant]
Arai, S. et al., “Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial”, Cytotherapy, vol. 10(6), pp. 625-632, (2008). [cited by applicant]
Tonn, T. et al., “Treatment of patients with advanced cancer with the natural killer cell line NK-92”, Cytotherapy, vol. 15(12), pp. 1563-1570, (Dec. 2013). [cited by applicant]
Klingermann, H. et al., “Natural killer cells for immunotherapy—advantages of the NK-92 cell line over blookd NK cells”, Frontiers in Immunology, vol. 7, pp. 1-7, (Mar. 2016). [cited by applicant]
Pinz, K. et al., “Targeting T-cell malignancies using anti-CD4 Car NK-92 cells”, Oconotarget, vol. 8(68), pp. 112783-112796, (2017). [cited by applicant]
Zhao, Y. et al., “A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity”, Journal of Immunology, vol. 183(9), pp. 5563-… [cited by applicant]
Enblad, G. et al., “Third generation CD19-CAR T cells for relapsed and refractory lymphoma and leukemia report from the Swedish Phase I/IIa trial”, Blood, vol. 126(23), (Dec. 2015). [cited by applicant]
Tam, Y. et al., “Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy”, Cytotherapy, vol. 5(3), pp… [cited by applicant]
Tonn, T. et al., “Cellular immunotherapy of malignancies using the clonal natural killer line NK-92”, Journal of Hematotherapy & Stem Cell Research, vol. 10(4), https://doi.org/10.1089/15258160152509145, (Jul. 2004). [cited by applicant]
Williams, B. et al., “A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy”, Oncotarget, vol. 8(51)… [cited by applicant]
Zhang, J. et al., “Natural killer cells and current applications of chimeric antigen receptor-modified NK-92 cells in tumor immunotherapy”, Intl. J. of Molecular Sciences, vol. 20(317), pp. 1-20, (2019). [cited by applicant]
Oelsner, S. et al., “Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma”, Cytotherapy, vol. 19(2), pp. 235-249, Online article: http://orca.cf.ac.uk/96745, (Apr. 2… [cited by applicant]
Boublikova, L. et al., “Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors”, Cancer Letters, vol. 376(2), pp. 367-376, doi: https://doi.org/10.1016/j.canlet.2016.04.016, (Jul. 20… [cited by applicant]
Gong, J. et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells”, Leukemia, vol. 8(4), pp. 652-658, (Apr. 1994). [cited by applicant]
Birkholz, K. et al., “A fast and robust method to clone and functionally validate T-cell receptors”, J. Immunol. Methods, vol. 346(1-2), pp. 45-54, doi: 10.1016/j.jim.2009.05.001, (Jul. 2009). [cited by applicant]
Szymczak, A. et al., “Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector”, Nat. Biotechnol., vol. 22(5), pp. 589-594, doi: 10.1038/nbt957, (May 2004). [cited by applicant]